Methoxy polyethylene glycol-epoetin beta biosimilar - Intas Biopharmaceuticals

Drug Profile

Methoxy polyethylene glycol-epoetin beta biosimilar - Intas Biopharmaceuticals

Latest Information Update: 04 Nov 2013

Price : $50

At a glance

  • Originator Intas Biopharmaceuticals
  • Class Antianaemics; Colony-stimulating factors; Erythropoietins; Haematopoietic cell growth factors; Polyethylene glycols
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Anaemia

Most Recent Events

  • 04 Nov 2013 Clinical trials in Anaemia in India (SC)
  • 04 Nov 2013 Intas Biopharmaceuticals plans a phase III trial for Anaemia associated with chronic kidney disease in India (CTRI2013-09-003956)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top